更新于：2024-11-01

CD51 x αvβ5 x αvβ3

更新于：2024-11-01

基本信息

关联

项与 CD51 x αvβ5 x αvβ3 相关的药物

JNJ-26076713

靶点

CD51 x αvβ3 x αvβ5

作用机制

CD51拮抗剂 [+2]

在研机构

Johnson & Johnson Pharmaceutical Research & Development LLC [+1]

原研机构

Johnson & Johnson Pharmaceutical Research & Development LLC

在研适应症

年龄相关性黄斑变性 [+2]

非在研适应症-

最高研发阶段临床前

首次获批国家/地区-

首次获批日期1800-01-20

100 项与 CD51 x αvβ5 x αvβ3 相关的临床结果

登录后查看更多信息

100 项与 CD51 x αvβ5 x αvβ3 相关的转化医学

登录后查看更多信息

0 项与 CD51 x αvβ5 x αvβ3 相关的专利（医药）

登录后查看更多信息

项与 CD51 x αvβ5 x αvβ3 相关的文献（医药）

2020-06-01·Immunology3区 · 医学

Regulation of barrier immunity and homeostasis by integrin‐mediated transforming growth factor β activation

3区 · 医学

Review

作者: Travis, Mark A. ; Gunaltay, Sezin ; McEntee, Craig P.

SummaryTransforming growth factor β (TGF‐β) is a multifunctional cytokine that regulates cell growth, differentiation, adhesion, migration and death dependent on cell type, developmental stage, or tissue conditions. Various cell types secrete TGF‐β, but always as an inactive complex. Hence, for TGF‐β to function, this latent complex must somehow be activated. Work in recent years has highlighted a critical role for members of the αv integrin family, including αvβ1, αvβ3, αvβ5, αvβ6 and αvβ8 that are involved in TGF‐β activation in various contexts, particularly at barrier sites such as the gut, lung and skin. The integrins facilitating this context‐ and location‐specific regulation can be dysregulated in certain diseases, so are potential therapeutic targets in a number of disorders. In this review, we discuss the role of TGF‐β at these barrier sites with a focus on how integrin‐mediated TGF‐β activation regulates tissue and immune homeostasis, and how this is altered in disease.

2019-08-01·Clinical and Translational Oncology3区 · 医学

A comparative assessment of the effects of integrin inhibitor cilengitide on primary culture of head and neck squamous cell carcinoma (HNSCC) and HNSCC cell lines

3区 · 医学

Article

作者: Açil, Y ; Purcz, N ; Gülses, A ; Weimer, J ; Wiltfang, J ; Zhang, L

BACKGROUNDIntegrins are highly attractive targets in oncology due to their involvement in angiogenesis in a wide spectrum of cancer entities. Among several integrin inhibitors, cilengitide is suggested to be one of the most promising inhibitors. However, little is known about the cellular processes induced during cilengitide chemotherapy in head and neck squamous cell carcinoma (HNSCC).MATERIALS AND METHODSFor the current study, 3 HNSCC cell lines, SCC4, SCC15 and SCC25; and 3 primary culture cells, TU53, TU57, and TU63 were used. CD90, cytokeratin, and vimentin were stained immunohistochemically to identify the biological characteristics of these cell lines and primary culture cells and the cytostatic effect of cilengitide was evaluated. Quantitative polymerase chain reaction (qPCR) arrays were applied to evaluate target protein genes ITGAV, ITGB3, and ITGB5 of integrin αvβ3 and αvβ5 at respective concentrations of 50 and 100 μM cilengitide for 72 h.RESULTSCilengitide has significantly inhibited the proliferation of HNSCC cells in a dose-dependent way. At the same concentration, cilengitide suppressed the proliferation of primary culture cells even more strongly than it did that of cell lines, suggesting that primary culture cells retain more of their internal biological characteristics than do cell lines. qPCR assay detected downregulation of ITGAV, ITGB3, and ITGB5 gene expression after exposure to 50 μM of cilengitide. However, after exposure to 100-μM cilengitide, expression of these genes significantly increased both in cell lines and primary culture cells.CONCLUSIONSRGD-containing small-molecule synthetic peptides might be considered in tumor chemotherapy in the near future. The different reactions of primary culture cells and cell lines demonstrated that individualized chemotherapy plans may be a feasible option. However, research on the role of cilengitide in HNSCC therapy is still in its early stages, and further investigations are required.

2016-01-01·Biochemical and Biophysical Research Communications3区 · 生物学

Integrin αVβ3 and αVβ5 are required for leukemia inhibitory factor-mediated the adhesion of trophoblast cells to the endometrial cells

3区 · 生物学

Article

作者: Chung, Tae-Wook ; Kim, Hyung Sik ; Park, Mi-Ju ; Choi, Hee-Jung ; Ha, Ki-Tae

The embryo implantation including adhesion between trophoblast and endometrium is a crucial process for the successful pregnancy. LIF and adhesion molecules including integrins are known as significant factors for embryo implantation. However, the function of LIF on the regulation of adhesion molecule expression and promotion of trophoblast adhesion to endometrial cells has not been fully elucidated. Here we show that LIF significantly induced mRNA expression of ITGAV, ITGB3, and ITGB5 in endometrial cells, as evidenced by RT-PCR and qRT-PCR analysis. Based on the results from treatment of antagonist for LIF receptor (hLA), LIF positively regulates expression of integrin αV, β3, and β5, and adhesion of the human trophectoderm-derived JAr cells to endometrial Ishikawa cells. Furthermore, the adhesion between trophoblastic cells and LIF-stimulated endometrial cells was significantly reduced by neutralization of LIF-mediated integrin β3 and β5 expression on endometrial cell surface with integrin subunit β3 and β5 antibodies. Taken together, we firstly demonstrate that LIF enhances the adhesion of trophoblastic cells to endometrial cells by up-regulating expression of integrin heterodimer αVβ3 and αVβ5, indicating the promotion of endometrial receptivity for embryo implantation.